Nanoparticle-mediated peptide delivery for breast cancer

纳米颗粒介导的肽递送用于乳腺癌

• 批准号: 8113621
• 负责人: Jordan Green
• 金额: $ 21.4万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-01 至 2013-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8113621
• 关键词: Apoptosis; Apoptotic; Biocompatible Materials; Biological; Biological Assay; Bioreactors; Blood Vessels; Breast Cancer Cell; Caliber; Cell Migration Inhibition function; Cell Proliferation; Cells; Development; Drug Delivery Systems; Drug Formulations; Encapsulated; Endothelial Cells; Engineering; Exhibits; Growth; Half-Life; Human; Implant; In Vitro; Individual; Injection of therapeutic agent; Laboratories; Lead; Libraries; Lymphatic Endothelial Cells; Malignant Neoplasms; Measures; Mediating; Medical; Methodology; Methods; Migration Assay; Modeling; Monitor; Mus; Patient Care; Peptides; Pharmaceutical Preparations; Polymers; Property; Proteins; Research; SCID Mice; Screening procedure; System; Testing; Time; Work; angiogenesis; antiangiogenesis therapy; base; biodegradable polymer; cell motility; design; experience; in vitro testing; in vivo; killings; malignant breast neoplasm; meetings; mouse model; nanobiotechnology; nanomedicine; nanoparticle; new technology; novel; prevent; subcutaneous; tumor; tumor xenograft

DESCRIPTION (provided by applicant): Many forms of cancer, including breast cancer, are dependent on angiogenesis, the growth of blood vessels. There is a great medical need for the development of a safe, effective, and inexpensive means of antiangiogenic therapy. One promising approach is the use of antiangiogenic peptides as the active agents. We have identified novel peptides derived from several classes of proteins that are effective at preventing angiogenesis in our preliminary studies. We have also identified other peptides able to inhibit cancer through additional mechanisms including antilymphangiogenesis and apoptosis. However, in their current form, all of these peptides have a short in vivo half-life and they are not suitable for systemic administration or for long-term action. Thus, there is a need to package, protect, and deliver these peptides in a more stable, sustained fashion. We seek to create new technology to meet this challenge and hypothesize that combinations of these peptides delivered in an engineered fashion could enable synergistic killing of breast cancer. Building on our experience with drug delivery nanoparticles, we will design an effective array of safe, biodegradable polymers for use in forming peptide-containing nanoparticles (Aim 1). These biomaterials will be used to construct nanoparticles that vary in their biophysical properties and in biological properties including tumor accumulation and peptide release. High-throughput synthesis and screening methodology will be used to select for novel nanoparticle formulations, including antiangiogenic peptide nanoparticles, highly efficient for inhibition of human endothelial cell proliferation and migration, inhibition lymphatic endothelial cell proliferation and migration, and promotion of breast cancer apoptosis. Our preliminary work shows these methods are practical and that we can synthesize new nanobiotechnology that performs superiorly to free unencapsulated peptide. In Aim 2, lead nanoparticles containing lead anti-cancer peptides from the in vitro screens in Aim 1 will then be utilized in vivo. Angiogenesis bioreactors implanted subcutaneously in mice will be used to monitor delivery of antiangiogenic peptides by the nanoparticles. The top-performing antiangiogenic formulation will be combined with other lead anti-cancer peptides and tested in a breast cancer mouse model. We aim to create new bionanotechnology that can safely, effectively, and relatively inexpensively treat breast cancer. PUBLIC HEALTH RELEVANCE: This research aims to create new bionanotechnologies that enable the efficient delivery of novel antiangiogenic, antilymphangiogenic, and pro-apoptotic peptides. The nanoparticles proposed here can facilitate the delivery of these peptides to systemically treat breast cancer.

描述（由申请人提供）：许多形式的癌症，包括乳腺癌，都依赖于血管生成，血管的生长。有一个伟大的医疗需求的发展，安全，有效，和廉价的手段抗血管生成治疗。一种有前途的方法是使用抗血管生成肽作为活性剂。在我们的初步研究中，我们已经鉴定了来自几类蛋白质的新型肽，这些肽在预防血管生成方面是有效的。我们还鉴定了能够通过其他机制抑制癌症的其他肽，包括抗淋巴管生成和细胞凋亡。然而，在它们目前的形式中，所有这些肽具有短的体内半衰期，并且它们不适合全身施用或长期作用。因此，需要以更稳定、持续的方式包装、保护和递送这些肽。我们寻求创造新技术来应对这一挑战，并假设以工程方式递送的这些肽的组合可以协同杀死乳腺癌。基于我们在药物递送纳米颗粒方面的经验，我们将设计一种有效的安全、可生物降解的聚合物阵列，用于形成含肽的纳米颗粒（目标1）。这些生物材料将用于构建纳米颗粒，这些纳米颗粒的生物物理特性和生物学特性（包括肿瘤积聚和肽释放）各不相同。高通量合成和筛选方法将用于选择新型纳米颗粒制剂，包括抗血管生成肽纳米颗粒，高效抑制人内皮细胞增殖和迁移，抑制淋巴管内皮细胞增殖和迁移，促进乳腺癌细胞凋亡。我们的初步工作表明，这些方法是实用的，我们可以合成新的纳米生物技术，表现优于游离未封装的肽。在目标2中，含有来自目标1中的体外筛选的铅抗癌肽的铅纳米颗粒然后将在体内使用。将使用皮下植入小鼠的血管生成生物反应器来监测纳米颗粒对抗血管生成肽的递送。这种性能最好的抗血管生成制剂将与其他领先的抗癌肽组合，并在乳腺癌小鼠模型中进行测试。我们的目标是创造新的生物纳米技术，可以安全，有效，相对便宜地治疗乳腺癌。 公共卫生相关性：这项研究旨在创造新的生物纳米技术，使新的抗血管生成，抗淋巴管生成和促凋亡肽的有效交付。这里提出的纳米颗粒可以促进这些肽的递送，以全身治疗乳腺癌。